{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:21:00Z","timestamp":1790785260373,"version":"4.1.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","pathologyjournal.rcpa.edu.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.pathol.2023.10.007","type":"journal-article","created":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T11:13:47Z","timestamp":1700910827000},"page":"81-91","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinicopathological analysis of CD47 and signal regulatory protein alpha expression in myeloid sarcoma patients: CD47 expression is a favourable prognostic factor"],"prefix":"10.1016","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6094-6522","authenticated-orcid":false,"given":"Ken","family":"Tanaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2356-3725","authenticated-orcid":false,"given":"Hiroaki","family":"Miyoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9040-285X","authenticated-orcid":false,"given":"Keisuke","family":"Kawamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasumasa","family":"Shimasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutaka","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teppei","family":"Imamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyohei","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3382-0473","authenticated-orcid":false,"given":"Mayuko","family":"Moritsubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6645-7818","authenticated-orcid":false,"given":"Takuya","family":"Furuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Kohno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinobu","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0211-3311","authenticated-orcid":false,"given":"Takashi","family":"Sonoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4996-5279","authenticated-orcid":false,"given":"Koichi","family":"Ohshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pathol.2023.10.007_bib1","first-page":"265","article-title":"Granulocytic sarcoma: a systematic review","volume":"3","author":"Yilmaz","year":"2013","journal-title":"Am J Blood Res"},{"key":"10.1016\/j.pathol.2023.10.007_bib2","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.clml.2017.02.027","article-title":"Myeloid sarcoma: presentation, diagnosis, and treatment","volume":"17","author":"Almond","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.pathol.2023.10.007_bib3","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1097\/PAS.0000000000000727","article-title":"Clinicopathological, cytogenetic, and prognostic analysis of 131 myeloid sarcoma patients","volume":"40","author":"Kawamoto","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.pathol.2023.10.007_bib4","doi-asserted-by":"crossref","first-page":"3544","DOI":"10.1200\/JCO.2016.67.5892","article-title":"Extramedullary disease in adult acute myeloid leukemia is common but lacks independent significance: analysis of patients in ECOG-ACRIN cancer research group trials, 1980\u20132008","volume":"34","author":"Ganzel","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2023.10.007_bib5","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.biopha.2012.10.014","article-title":"Is there a \u201cgold\u201d standard treatment for patients with isolated myeloid sarcoma?","volume":"67","author":"Antic","year":"2013","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.pathol.2023.10.007_bib6","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/sj.leu.2404491","article-title":"Myeloid sarcoma: clinico pathologic, phenotypic and cytogenetic analysis of 92 adult patients","volume":"21","author":"Pileri","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.pathol.2023.10.007_bib7","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1002\/cncr.10399","article-title":"Comparison in treatment of nonleukemic granulocytic sarcoma","volume":"94","author":"Yamauchi","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.pathol.2023.10.007_bib8","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/S0962-8924(00)01906-1","article-title":"Integrin-associated protein (CD47) and its ligands","volume":"11","author":"Brown","year":"2001","journal-title":"Trends Cell Biol"},{"key":"10.1016\/j.pathol.2023.10.007_bib9","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ejca.2017.02.013","article-title":"Cancer immunotherapy targeting the CD47\/SIRP\u03b1 axis","volume":"76","author":"Weiskopf","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.pathol.2023.10.007_bib10","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/imr.12527","article-title":"The CD47- SIRP\u03b1 signaling axis as an innate immune checkpoint in cancer","volume":"276","author":"Matlung","year":"2017","journal-title":"Immunol Rev"},{"key":"10.1016\/j.pathol.2023.10.007_bib11","doi-asserted-by":"crossref","first-page":"10133","DOI":"10.18632\/oncotarget.7100","article-title":"A\u00a0function-blocking CD47 antibody suppresses stem cell and EGF signaling in triple-negative breast cancer","volume":"7","author":"Kaur","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.pathol.2023.10.007_bib12","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.canlet.2015.02.036","article-title":"Antibody mediated therapy targeting CD47 inhibits tumor progression of hepatocellular carcinoma","volume":"360","author":"Xiao","year":"2015","journal-title":"Cancer Lett"},{"key":"10.1016\/j.pathol.2023.10.007_bib13","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1172\/JCI81603","article-title":"CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer","volume":"126","author":"Weiskopf","year":"2016","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.pathol.2023.10.007_bib14","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/bjc.2017.173","article-title":"CD47 overexpression is associated with decreased neutrophil apoptosis\/phagocytosis and poor prognosis in non-small-cell lung cancer patients","volume":"117","author":"Barrera","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1016\/j.pathol.2023.10.007_bib15","first-page":"2901","article-title":"Overexpression of CD47 predicts poor prognosis and promotes cancer cell invasion in high-grade serous ovarian carcinoma","volume":"9","author":"Li","year":"2017","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.pathol.2023.10.007_bib16","doi-asserted-by":"crossref","first-page":"801","DOI":"10.3892\/ol.2017.6257","article-title":"Significance of CD47 expression in gastric cancer","volume":"14","author":"Sudo","year":"2017","journal-title":"Oncol Lett"},{"key":"10.1016\/j.pathol.2023.10.007_bib17","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.89140","article-title":"Anti-SIRP\u03b1 antibodies as a potential new tool for cancer immunotherapy","volume":"2","author":"Yanagita","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.pathol.2023.10.007_bib18","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2009.05.046","article-title":"CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis","volume":"138","author":"Jaiswal","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.pathol.2023.10.007_bib19","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.cell.2009.05.045","article-title":"CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells","volume":"138","author":"Majeti","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.pathol.2023.10.007_bib20","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1158\/0008-5472.CAN-10-2238","article-title":"Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia","volume":"71","author":"Chao","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.pathol.2023.10.007_bib21","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.cell.2010.07.044","article-title":"Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma","volume":"142","author":"Chao","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.pathol.2023.10.007_bib22","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1038\/leu.2012.141","article-title":"Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells","volume":"26","author":"Kim","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.pathol.2023.10.007_bib23","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid\u00a0and\u00a0histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.pathol.2023.10.007_bib24","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1002\/hon.2506","article-title":"Expression of programmed death ligand 1 is associated with poor prognosis in myeloid sarcoma patients","volume":"36","author":"Kawamoto","year":"2018","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.pathol.2023.10.007_bib25","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1002\/1097-0142(19810915)48:6<1426::AID-CNCR2820480626>3.0.CO;2-G","article-title":"Granulocytic sarcoma: a clinicopathologic study of 61 biopsied cases","volume":"48","author":"Neiman","year":"1981","journal-title":"Cancer"},{"key":"10.1016\/j.pathol.2023.10.007_bib26","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1080\/10428190600967196","article-title":"Granulocytic sarcoma: 32 cases and review of the literature","volume":"47","author":"Paydas","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.pathol.2023.10.007_bib27","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1182\/blood.V42.5.721.721","article-title":"Chloroma and other myeloblastic tumors","volume":"42","author":"Muss","year":"1973","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2023.10.007_bib28","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical\u00a0practice guideline focused update","volume":"36","author":"Wolff","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2023.10.007_bib29","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/ajco.12263","article-title":"Human epidermal growth factor 2 testing in gastric cancer: recommendations of an Asia-Pacific task force","volume":"10","author":"Kim","year":"2014","journal-title":"Asia Pac J Clin Oncol"},{"key":"10.1016\/j.pathol.2023.10.007_bib30","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.immuni.2020.04.011","article-title":"The CD47- SIRP\u03b1 immune checkpoint","volume":"52","author":"Logtenberg","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.pathol.2023.10.007_bib31","doi-asserted-by":"crossref","first-page":"451","DOI":"10.3390\/cancers13030451","article-title":"Cancer of unknown primary: challenges and progress in clinical management","volume":"13","author":"Laprovitera","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.pathol.2023.10.007_bib32","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1755-8794-2-69","article-title":"A\u00a0taxonomy of epithelial human cancer and their metastases","volume":"2","author":"Gevaert","year":"2009","journal-title":"BMC Med Genom"},{"key":"10.1016\/j.pathol.2023.10.007_bib33","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s40291-015-0133-8","article-title":"Poorly differentiated neoplasms of unknown primary site: siagnostic usefulness of a molecular cancer classifier assay","volume":"19","author":"Greco","year":"2015","journal-title":"Mol Diagn Ther"},{"key":"10.1016\/j.pathol.2023.10.007_bib34","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.4049\/jimmunol.161.4.1853","article-title":"Signal-regulatory protein is selectively expressed by myeloid and neuronal cells","volume":"161","author":"Adams","year":"1990","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.pathol.2023.10.007_bib35","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.1182\/blood.V94.11.3633","article-title":"Human signal-regulatory protein is expressed on normal, but not on subsets of leukemic myeloid cells and mediates cellular adhesion involving its counterreceptor CD47","volume":"94","author":"Seiffert","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2023.10.007_bib36","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1111\/cas.14437","article-title":"Combination of CD47 and signal-regulatory protein-\u03b1 constituting the \u201cdon\u2019t eat me signal\u201d is a prognostic factor in diffuse large B-cell lymphoma","volume":"111","author":"Kazama","year":"2020","journal-title":"Cancer Sci"},{"key":"10.1016\/j.pathol.2023.10.007_bib37","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1002\/hon.2768","article-title":"Clinicopathological analysis of immunohistochemical expression of CD47 and SIRP\u03b1 in adult T-cell leukemia\/lymphoma","volume":"38","author":"Yanagida","year":"2020","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.pathol.2023.10.007_bib38","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa041869","article-title":"Prediction of survival in follicular lymphoma based on molecular features of tumorinfiltrating immune cells","volume":"351","author":"Dave","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pathol.2023.10.007_bib39","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/bloodadvances.2018018754","article-title":"Microenvironmental immune cell signatures dictate clinical outcomes for PTCL-NOS","volume":"2","author":"Sugio","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.pathol.2023.10.007_bib40","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.3389\/fonc.2019.01380","article-title":"Therapeutic targeting of the macrophage immune checkpoint CD47 in myeloid malignancies","volume":"9","author":"Chao","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.pathol.2023.10.007_bib41","doi-asserted-by":"crossref","first-page":"5630","DOI":"10.4238\/2015.May.25.15","article-title":"Ara-C and anti-CD47 antibody combination therapy eliminates acute monocytic leukemia THP-1 cells in\u00a0vivo and in\u00a0vitro","volume":"14","author":"Wang","year":"2015","journal-title":"Genet Mol Res"},{"key":"10.1016\/j.pathol.2023.10.007_bib42","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00277-021-04734-2","article-title":"Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed\/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes","volume":"101","author":"Zeidan","year":"2022","journal-title":"Ann Haematol"},{"key":"10.1016\/j.pathol.2023.10.007_bib43","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa1807315","article-title":"CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin's lymphoma","volume":"379","author":"Advani","year":"2018","journal-title":"N\u00a0Engl J Med"}],"container-title":["Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302523003021?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302523003021?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T16:30:35Z","timestamp":1758472235000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031302523003021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S0031302523003021"],"URL":"https:\/\/doi.org\/10.1016\/j.pathol.2023.10.007","relation":{},"ISSN":["0031-3025"],"issn-type":[{"value":"0031-3025","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinicopathological analysis of CD47 and signal regulatory protein alpha expression in myeloid sarcoma patients: CD47 expression is a favourable prognostic factor","name":"articletitle","label":"Article Title"},{"value":"Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pathol.2023.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Royal College of Pathologists of Australasia. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}